Browsing publications by Dr Julie Irving

Newcastle AuthorsTitleYearFull text
Judith Weiland
Dr Deepali Pal
Marian Case
Dr Julie Irving
Dr Frida Ponthan
et al.
BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance2016
Rosie Jackson
Dr Julie Irving
Dr Gareth Veal
Personalisation of dexamethasone therapy in childhood acute lymphoblastic leukaemia2016
Dr Julie Irving
Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia2016
Professor Anthony Moorman
Dr Julie Irving
Dr Amir Enshaei
Dr Amy Erhorn
Lynne Minto
et al.
Composite Index for Risk Prediction in Relapsed Childhood Acute Lymphoblastic Leukaemia2015
Zach Dixon
Dr Lindsay Nicholson
Dr Julie Irving
CREBBP Knockdown Does Not Impact on Glucocorticoid Induced Apoptosis in Childhood Acute Lymphoblastic Leukemia2015
Dr Sarah Fordham
Mike Cole
Dr Julie Irving
Professor James Allan
Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia2015
Dr Lindsay Nicholson
Emily Mavin
Lynne Minto
Dr Julie Irving
Professor Anne Dickinson
et al.
Gene Expression Profiling Implicates Attenuation of NFkB Signalling By Regulatory T Cells in Modulating Dendritic Cell Function2015
Dr Lindsay Nicholson
Elizabeth Matheson
Lynne Minto
Christopher Keilty
Maryna Sanichar
et al.
Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition2015
Dr Julie Irving
Elizabeth Matheson
Helen Blair
Marian Case
Isabella Swidenbank
et al.
Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420-34302015
Professor Anthony Moorman
Dr Julie Irving
Professor James Allan
Professor Christine Harrison
The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A2015
1234567891011